If the company maintains its projected 20% top-line revenue growth rate—bolstered by the integration of Amicus and Voxzogo's continued geographic expansion—the forward earnings yield represents deep value. Consequently, consensus analyst targets average between $75.00 and $91.62 per share, representing upside potential of roughly 16% to 50% from recent trading levels in the mid-$60s (Koala Gains).
Strategic Consolidation: The Amicus, Alesta, and Ascendis Maneuvers
BioMarin’s executive leadership has aggressively shifted the corporate strategy from purely organic, high-risk genetic research toward commercial-stage asset consolidation. Three major transactions highlight this strategy of building impenetrable therapeutic moats.
The Amicus Therapeutics Acquisition
The centerpiece of BioMarin's commercial strategy is the $4.8 billion Amicus acquisition. By absorbing Amicus, BioMarin secured two highly lucrative, de-risked commercial assets: 1. POMBILITI + OPFOLDA: Discussed in the clinical section above, projected to hit $1.2 billion in peak sales by the mid-to-late 2030s. 2. Galafold (migalastat): The first oral treatment for Fabry disease. Through recent patent litigation settlements, U.S. market exclusivity for Galafold is secured through January 2037. BioMarin projects Galafold's peak revenue to reach approximately $1.4 billion by the mid-2030s. Price/Cost: Galafold has an average U.S. list price of approximately $315,000 per year, competing directly with Sanofi's infused Fabrazyme (which costs roughly $340,000 annually) (BioPharma Dive; Drugs.com). Availability: Broadly available in the US, EU, Japan, and several other global markets. Context & Anti-Use Case: As a "chaperone" therapy, Galafold is explicitly not for all Fabry patients. It is uniquely indicated only for individuals possessing one of roughly 348 specific "amenable" mutations of the GLA gene. Patients lacking an amenable mutation are entirely contraindicated and must rely on standard intravenous enzyme replacement therapy.
Furthermore, the acquisition included U.S. rights to BMN 820 (formerly DMX-200), a Phase 3 oral small molecule targeting focal segmental glomerulosclerosis (FSGS), a rare kidney disease with a total addressable U.S. market of 30,000 patients. The Amicus portfolio is immediately revenue-accretive and dramatically diversifies BioMarin's reliance on VOXZOGO.
The Alesta Therapeutics Buyout
Continuing its bolt-on acquisition spree, BioMarin acquired Alesta Therapeutics in August 2026 for $275 million upfront, with an additional $215 million tied to regulatory and development milestones (Fierce Biotech). This deal brings ALE1 into BioMarin's Skeletal Conditions Business Unit.
ALE1 is an orally active small molecule designed to treat hypophosphatasia (HPP), a rare genetic bone disease characterized by impaired bone mineralization, frequent fractures, and muscle weakness. Currently in Phase 1/2a trials targeting adults, ALE1 lowers inorganic pyrophosphate (PPi), the central disease metabolite. If approved, it would be the first oral therapy for HPP, providing a highly desirable alternative to current lifelong injectable regimens like AstraZeneca's Strensiq* (which requires injections three to six times a week). By spinning out Alesta's non-core assets and taking on zero new employees, BioMarin structured a lean transaction that captures the asset's full upside without bloated operational overhead (Global Genes).
The Ascendis Pharma Royalty Settlement
In a masterclass of intellectual property monetization, BioMarin neutralized a significant competitive threat while generating a massive, high-margin revenue stream. BioMarin had been engaged in global patent litigation against Ascendis Pharma regarding Ascendis's achondroplasia drug, Yuviwel (navepegritide), arguing that the drug infringed on BioMarin's C-type natriuretic peptide (CNP) patents protecting VOXZOGO.
In August 2026, the two companies reached a binding global settlement (BioSpace). BioMarin granted Ascendis a non-exclusive license to commercialize Yuviwel across all indications. In exchange, Ascendis will pay BioMarin a staggering royalty rate of 20% on net sales in the United States and 18% on net sales in the European Union, Brazil, and South Korea, running through May 2030 (Ascendis PR).
This settlement is profoundly bullish for BioMarin. Royalty rates in biotech settlements rarely approach 20%. BioMarin effectively co-opted its largest competitor, ensuring that even if Yuviwel captures market share from VOXZOGO, BioMarin still collects a massive margin on every competitor sale with absolutely zero associated marketing, manufacturing, or distribution costs. Ascendis generated €8 million in Yuviwel revenues in Q2 2026 alone, highlighting the immediate financial impact of this royalty structure (TradingView).
